

**AMENDMENT AND RESPONSE TO DECISION BY BOARD OF APPEALS**

The Commissioner is hereby authorized to charge our Deposit Order Account No. 50-1868 in the amount of \$55.00, which represents the fee for filing a Terminal Disclaimer for a small entity. It is believed that no additional fee is required. However, should an additional fee be required, the Commissioner is hereby authorized to charge the additional fees to Deposit Account No. 50-1868.

**IN THE CLAIMS**

11. A complementary compound comprising hydrogen bond donor and acceptor sites arranged to specifically bind [binding to] and inhibit [inhibiting] the function of a targeted RNA molecule, wherein the compound is specifically directed to and binds to a critical region of the RNA molecule, located within the minor groove of the RNA molecule, identified by a combination of the primary, secondary and tertiary structure of the critical region.

12. The complementary compound of claim 11 wherein the RNA is selected from the group consisting of mRNA, tRNA, rRNA, and viral RNA.

13. The complementary compound of claim 11 further comprising a pharmaceutically acceptable carrier selected from the group consisting of pharmaceutically acceptable compositions for topical administration, pharmaceutically acceptable compositions for parenteral administration, pharmaceutically acceptable compositions for enteral administration, and combinations thereof.

17. The complementary compound of claim 12 wherein the compound binds to a critical region within the minor groove of the acceptor stem of a tRNA molecule.

18. The complementary compound of claim 17 wherein the tRNA molecule is tRNA<sup>Ala</sup>.